AMRN

Vascepa

Cardiovascular Disease / Triglycerides

ANDA Litigation

Exp Date

9/2/2020

Amp Volatility Score

41%

Catalyst Info & Data Links

TITLE: AMRN ANDA litigation - oral arguments with federal circuit panel


WHAT IS NEXT CATALYST EVENT?

  • Oral arguments with federal circuit panel


WHEN WILL THE EVENT (OR DID THE EVENT) OCCUR?

  • Sept 2, 2020 - oral arguments with federal circuit panel


DOES AMP THINK THIS EVENT IS LIKELY TO MOVE THE STOCK, AND IF SO HOW MUCH?


KEY UPCOMING EVENTS:

  • 1st week Aug, SEPT, OCT, or NOV - oral arguments with federal circuit panel
  • Late 2020/early 2021 - Federal Circuit panel reaches its decision and publishes opinion


  • Become a Premium subscriber ((CLICK HERE TO SIGN UP)) and get an upgraded version of this schedule including an event NOT being considered by many investors, that could have an important impact on the outcome of the appeal, and access to AMP's articles on key events.


PRIOR DATA/EVENTS

  • May 12, 2020 - AMRN's Appeal Brief - FILED (attached to this post)
  • June 16, 2020 - Generic companies Response brief
  • June 26, 2020 - AMRN's Reply brief
  • July 1, 2020 - Joint Appendix to appeal record due


  • Become a Premium subscriber and get copies of prior briefs filed in case as well as access to AMP's articles on the events of the case (CLICK HERE TO SIGN UP)


  • Become a Premium subscriber ((CLICK HERE TO SIGN UP)) and get an upgraded version of this schedule with copies of key filings in the litigation and access to AMP's detailed articles on key events.


Updated by HC

AMRN, ANDA_litigation

Prior Data (click to view full image)

Chart

Trial Design / Revenue (click to view full image)

Chart

Recent Posts

See What The Community Is Saying - Click To See Full Post

AMRN's Q2 VASCEPA® Net Sales...

AMRN reported a $135.3 million in net total revenue in Q2 2020, an increase of 34% over Q2 2019, resulting in H1 2020 net total revenue of $290.3 million, an increase of 67% over H1 2019. In addition...

AMARIN ANDA LITIGATION UPDATE:...

In our Amp Patent Investor subscription forum, I provide my analysis of the possible affect on the appellate court's ruling, of the recent scientific publication by the Reduce-It trial's principal inv...

Jackpot...

BINGO #winner #ZGNX #AMRN #AIMT...

AMRN Litigation Update | Possi...

Dr. Vacchiano, JD, PhD, analyzed the complex factual, regulatory and legal issues specifically related to Amarin's possible attempt to obtain a preliminary injunction from the court to stop a possible...

Experienced biotech patent att...

Check out my 20 minute video about the ongoing AMRN ANDA appeal. It includes valuable information include key dates in the litigation as well as the #1 misconception of biotech investors regarding thi...

AMRN Litigation Update - 5/19/...

On 5/19/20 the BIOTECHNOLOGY INNOVATION ORGANIZATION (BIO), the largest trade organization representing biotech companies and Universities filed an amicus brief in the Amarin appeal. The brief relates...

*Disclaimer: Information provided on ampbiotechresearch.com and in any of our reports, products and services are for information only and are not investment advice. Please consult with an investment adviser and do your own diligence before making any investment decisions or taking any action.  By accessing this site, you agree to our Terms of Use and Privacy Policy that can be accessed here. Amp Core™ is a trademark of Amp Biotech Research, LLC

©2020 BY Amp Biotech Research

  • Twitter Social Icon
  • LinkedIn Social Icon